ATE310002T1 - Imidazotriazin-derivate als gaba-rezeptor- liganden - Google Patents

Imidazotriazin-derivate als gaba-rezeptor- liganden

Info

Publication number
ATE310002T1
ATE310002T1 AT02747567T AT02747567T ATE310002T1 AT E310002 T1 ATE310002 T1 AT E310002T1 AT 02747567 T AT02747567 T AT 02747567T AT 02747567 T AT02747567 T AT 02747567T AT E310002 T1 ATE310002 T1 AT E310002T1
Authority
AT
Austria
Prior art keywords
receptor ligands
gaba receptor
derivatives
imidazotriazine
imidazotriazine derivatives
Prior art date
Application number
AT02747567T
Other languages
English (en)
Inventor
William Robert Carling
David James Hallett
Michael Geoffrey Neil Russell
Leslie Joseph Street
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE310002T1 publication Critical patent/ATE310002T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT02747567T 2001-07-16 2002-07-08 Imidazotriazin-derivate als gaba-rezeptor- liganden ATE310002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117277.4A GB0117277D0 (en) 2001-07-16 2001-07-16 Therapeutic agents
PCT/GB2002/003114 WO2003008418A1 (en) 2001-07-16 2002-07-08 Imidazo-triazine derivatives as ligands for gaba receptors

Publications (1)

Publication Number Publication Date
ATE310002T1 true ATE310002T1 (de) 2005-12-15

Family

ID=9918561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02747567T ATE310002T1 (de) 2001-07-16 2002-07-08 Imidazotriazin-derivate als gaba-rezeptor- liganden

Country Status (11)

Country Link
US (2) US6617326B2 (de)
EP (1) EP1409488B1 (de)
JP (1) JP4373780B2 (de)
AT (1) ATE310002T1 (de)
AU (1) AU2002317957B2 (de)
CA (1) CA2451445A1 (de)
DE (1) DE60207416T2 (de)
ES (1) ES2249598T3 (de)
GB (1) GB0117277D0 (de)
PE (1) PE20030432A1 (de)
WO (1) WO2003008418A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936608B2 (en) * 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
WO2005023256A1 (en) * 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (de) * 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (de) * 2006-09-19 2009-06-10 Braincells, Inc. Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
WO2015189744A1 (en) 2014-06-12 2015-12-17 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
US10079661B2 (en) 2015-09-16 2018-09-18 At&T Intellectual Property I, L.P. Method and apparatus for use with a radio distributed antenna system having a clock reference
MX2018009252A (es) 2016-01-27 2019-01-21 Univ Zuerich Uso de moduladores de receptores de gabaa para el tratamiento de picor.
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Gabaa陽性アロステリックモジュレーター化合物、その作製の方法および使用
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
CA3154222A1 (en) * 2019-10-22 2021-04-29 Matthew TOCZKO Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422194A (en) * 1967-08-15 1969-01-14 Smithkline Corp The treatment of depression with imidazo(1,2-b)-as-triazines and compositions thereof
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
WO2000078728A1 (en) * 1999-06-22 2000-12-28 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
AU783521B2 (en) 2000-05-24 2005-11-03 Merck Sharp & Dohme Limited 3-phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
US6936608B2 (en) 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors

Also Published As

Publication number Publication date
JP2004536862A (ja) 2004-12-09
ES2249598T3 (es) 2006-04-01
PE20030432A1 (es) 2003-05-17
DE60207416D1 (de) 2005-12-22
JP4373780B2 (ja) 2009-11-25
DE60207416T2 (de) 2006-08-03
GB0117277D0 (en) 2001-09-05
US6617326B2 (en) 2003-09-09
WO2003008418A1 (en) 2003-01-30
US20030216395A1 (en) 2003-11-20
US6696444B2 (en) 2004-02-24
US20030055060A1 (en) 2003-03-20
EP1409488B1 (de) 2005-11-16
EP1409488A1 (de) 2004-04-21
CA2451445A1 (en) 2003-01-30
AU2002317957B2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE310002T1 (de) Imidazotriazin-derivate als gaba-rezeptor- liganden
ATE310740T1 (de) Imidazotriazin-derivate als liganden für gaba- rezeptoren
DE60012044D1 (de) Imidazopyridinderivate als liganden für gaba-rezeptoren
GB0212048D0 (en) Therapeutic agents
BG108166A (en) Imidazo-pyrimidine derivatives as liigands for gaba receptors
DE60214532D1 (de) Imidazopyrimidin-derivate als liganden für gaba-rezeptoren
ATE371659T1 (de) Pyrazolotriazinderivate als gaba-rezeptorliganden
ATE284403T1 (de) Triazolopyridazinderivate als liganden für gaba- rezeptoren
ATE335741T1 (de) 8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren
ATE253066T1 (de) Imidazotriazinderivate als gaba rezeptor-liganden
DE60006835D1 (de) Imidazopyridinderivate als gaba rezeptor liganden
DE69911374D1 (de) Triazolopiridazinederivate als gaba rezeptor-liganden
EA200000783A1 (ru) Производные триазолопиридазина в качестве лигандов для гамк рецепторов
DE60325865D1 (de) Phenylpyridazin derivative als liganden für gaba-rezeptoren
JO2312B1 (en) Imidazo-pyrimidine derivatives as associative groups of JABA receptors
FR2828197B1 (fr) Nouveaux materiaux a base de derives de corrole pour le piegeage du monoxyde de carbone
AR035876A1 (es) Compuestos derivados de imidazo-triazina como ligandos para receptores gaba, composiciones farmaceuticas y uso de los compuestos en la fabricacion de medicamentos
PE44299A1 (es) Derivados sustituidos de triazolo-piridacina como ligandos para receptores gaba
DOP2002000440A (es) Derivados de imidazo-trizina como ligandos de los receptores gaba.
DK1419167T3 (da) 1-(2,5'-anhydro-lyxofuranosyl) thyminer til syntese af radiomarkerede fluor-3 doxynucleotider

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties